Researchers from Kanaph Therapeutics Inc. and Korea Research Institute of Chemical Technology have disclosed prostanoid EP2 and/or EP4 receptor subtype dual antagonists reported to be useful for the treatment of cancer.
Pharmabcine Inc. has received approval from the human research ethics committee (HREC) in Australia for a phase Ia/b trial of PMC-309, a monoclonal antibody against the human V-domain Ig suppressor of T-cell activation (VISTA) ligand.
Researchers from China Pharmaceutical University and Nanjing First Hospital synthesized and optimized a novel series of thiohydantoin based compounds leading to the discovery of candidate [I] as the lead androgen receptor (AR) antagonist (IC50=1.46 µM).
Cancer Research Technology Ltd. has disclosed proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding moiety covalently bonded to a mitogen-activated protein kinase 7 (MAPK7; ERK5)-targeting moiety through a linker. They are reported to be useful for the treatment of cancer.
Researchers from Xiamen University and affiliated organizations have reported the discovery of nuclear hormone receptor NUR/77 (Nur77) modulators as potential candidates for the treatment of hepatocellular carcinoma (HCC).
Researchers from Peking University Cancer Hospital presented the discovery and preclinical evaluation of [124I]IMMU-132, a trophoblast cell surface antigen 2 (Trop2)-targeting molecular probe for micro-PET imaging.
Integrin alphavbeta3 and aminopeptidase N (CD13) are important biomarkers involved in tumor angiogenesis, tumor growth and metastasis. Peptides RGD (Arg-Gly-Asp) and NGR (Asn-Gly-Arg) are the most studied peptides for targeting integrin alphavbeta3 and CD13, respectively.
Medigene AG has selected its lead candidate for MDG-2011, a T-cell receptor engineered T-cell (TCR-T) therapy targeting KRAS G12V with HLA-A*11 and being developed in combination with the company’s PD1-41BB costimulatory switch protein (CSP) technology.
Retinoic acid (RA) is fundamental to maintain immune homeostasis. In this process, RA induces regulatory T cells and promotes tolerance, but depending on the conditions, RA may also promote inflammation and tissue damage.